By Joel Wright, President, Pharmacy Services, VytlOne
Summary
Most health systems capture only a fraction of the 340B savings they are eligible for. The gap hides in eligibility screening, contract pharmacy management, and split billing, where manual processes and legacy tools miss cases that a modern 340B program would catch. Specialty pharmacy usually holds the largest uncaptured opportunity. The savings are rarely lost to carelessness. They are lost to a lack of visibility.
Expectations vs. reality
Ask most health system CEOs and CFOs how they think about pharmacy, and you will usually get one of two answers: it is a clinical department, or it is a cost center to manage carefully. Both are true as far as they go. But they miss the bigger picture.
Pharmacy, particularly 340B and specialty pharmacy, is one of the largest untapped revenue engines most systems have.
That is not a knock on anyone running these programs. The people managing 340B and specialty pharmacy today are capable, careful, and stretched thin. The real issue is that eligibility screening, manufacturer restrictions, contract pharmacy complexity, and split billing have grown far more complicated than the manual processes and legacy tools most systems still rely on.
It is not a talent gap. It is a tools gap.
How much 340B revenue are most health systems missing?
The 340B program represents billions in savings for eligible health systems, yet the average system captures only a fraction of what it is entitled to. In hundreds of gap analyses, we have found meaningful uncaptured savings in nearly every one we have run. The question usually is not whether the gap exists. It is how large it turns out to be.
Specialty pharmacy is where that gap, and the dollars, tend to concentrate. Complex therapies, oncology, rare disease, and transplants, are exactly where eligible patients slip through manual screening, and a well-run specialty pharmacy program at a 340B hospital can generate up to six times more revenue per prescription than a retail program. Most C-suites haven’t had that number put in front of them plainly. It deserves to be.
What closing the 340B gap looks like in practice
One system we work with, an 800-bed multi-campus health system, recognized $25 million in net new profit in its first year working with us. We are now tracking toward $50 million as we expand into additional service lines and pharmacy operations. That is not a hypothetical upside. It is what happens when a health system gets the visibility and infrastructure to capture what the program was always supposed to provide.
Closing that gap is the focus of our 340B optimization work, where the goal is simple: capture what the program was designed to deliver, and keep capturing it as the rules shift.
A financial shift worth your attention
The 340B rebate model pilot scheduled to take effect January 1, 2027 is a shift that belongs on your balance sheet, not off to the side in pharmacy. It is still moving, drawing active litigation and competing legislation, so the details may change. What does not change is the direction: more scrutiny, more complexity, and less room for a program you set up once and left alone.
Most executives have not had a real conversation yet about what it means for their organization. Not because they are not paying attention, but because so much else is competing for that attention right now.
Manufacturer restrictions, regulatory changes, and contract pharmacy rules are all moving at once. Systems that set up their 340B program once and left it alone are often surprised, years later, by how much savings quietly eroded.
Why the 340B gap is usually a data problem
When a pharmacy director says the program is performing well and the CFO is not so sure, that is rarely a disagreement about pharmacy. It is a visibility problem because no one has had the tools to see it clearly. The same visibility gap shows up across the system, which is why AI-driven pharmacy analytics has become a priority for health system leadership. Health systems fight hard for every dollar of payer reimbursement, then leave 340B savings unclaimed on the other side of the ledger, not out of carelessness, but because no one has had the tools to see it clearly. Recognizing $5 million a year in savings for a 500-bed hospital has leaders feeling good about the program. Learning it should be $19 to $22 million annually puts it in a different light. “Performing well” has to be measured against the potential to be meaningful.
This is the problem VytlAIQ was built to solve. Not a reporting layer bolted onto existing processes, but a platform built by people who have run these programs at scale and know exactly where the gaps hide. It does not replace your pharmacy team. It gives them the visibility and speed to stay ahead of an environment that manual processes were never built to handle. Using AI this way responsibly matters as much as using it at all, which is why we hold our 340B tools to the standards laid out in responsible AI in 340B.
The strongest 340B programs I have seen have one thing in common: the CFO and the pharmacy director are looking at the same numbers, in the same room, at the same time. That alignment is rarer than it should be, but when it happens, the results are not incremental.
How to know if your 340B program is capturing enough
Your pharmacy program is either funding your mission or quietly limiting it. There is not much middle ground. Within a reasonable range, we can usually tell you what a health system your size should be capturing from 340B, and what most systems your size actually capture. The gap between those two numbers is usually where the conversation gets interesting.
If you have not had that conversation yet, now is a good time to start. The environment is not getting simpler, and the systems that get ahead of it are the ones that stop treating pharmacy as a cost to manage and start treating it as the asset it is.
Key takeaways
- Most health systems capture only a fraction of the 340B savings they are eligible for. The gap is a tools problem, not a talent problem.
- Specialty pharmacy holds the largest uncaptured opportunity, up to six times more revenue per prescription than a retail program.
- The 340B rebate model change expected in January 2027 makes this a balance-sheet priority, not a back-office one.
- The core barrier is visibility. When the CFO and pharmacy director see the same numbers, the results are not incremental.
Frequently asked questions
How much 340B revenue do most health systems miss?
Most capture only a fraction of what they are eligible for. In hundreds of gap analyses, we have found meaningful uncaptured savings in nearly every one. For a 500-bed hospital, a program recognizing $5 million a year in savings should often be capturing $19 to $22 million. The uncaptured dollars concentrate in specialty pharmacy and in eligibility cases that manual screening misses.
Why do health systems leave 340B savings unclaimed?
Not through carelessness. Eligibility screening, manufacturer restrictions, contract pharmacy complexity, and split billing have outgrown the manual processes most systems still use. The savings are left on the table because teams have not had the tools to see them clearly.
How does specialty pharmacy affect 340B revenue?
Specialty pharmacy is where the largest uncaptured savings concentrate. Complex therapies in oncology, rare disease, and transplant are where eligible patients slip through manual screening, and a well-run specialty program at a 340B hospital can generate up to six times more revenue per prescription than a retail one.
Compare what a system of your size should be capturing against what it actually captures. That gap, sized through a 340B optimization review, is the clearest signal of whether a program is performing or just appearing to.
Learn more
Visit VytlAIQ to see what your 340B program should be capturing.
Joel Wright is a registered pharmacist and the President of Pharmacy Services at VytlOne. He has over 30 years of healthcare experience across retail operations, specialty pharmacy, managed pharmacy, health system and center pharmacy operations, and home infusion. Joel is dedicated to patient care, improving patient outcomes, and optimizing healthcare processes through innovation.